Charles Lapp

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Source: Hunter-Hopkins Center

Charles W. Lapp, MD, is an Internist and the Medical Director Emeritus at Hunter-Hopkins Center in Charlotte, North Carolina, USA, which has a practice specializing in ME/CFS, FM, and related conditions. Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.[1] He became interested in ME/CFS following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. One of these outbreaks was among all the members of the N.C. Symphony Orchestra.

"Patients started coming to me with persistent flulike symptoms[...]They would work one day and have to sleep for two. Perfectly well-adjusted people became disabled almost overnight.”[2]

From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. Paul Cheney. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center.[3] His center does testing for disability insurance such as the 2-day Cardiopulmonary exercise testing (CPET) and a Computer-assisted cognitive function test.

Following Dr. Lapp's retirement in 2017, the Hunter-Hopkins Center director became Dr. Vincent F. Hillman and includes Dr. Laura Black on staff.[4]

Awards[edit | edit source]

  • 2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by IACFS/ME[5]

IOM Committee on Diagnostic Criteria for ME/CFS[edit | edit source]

Dr Lapp was a reviewer for the 2015 report produced by the Institute of Medicine's Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[6]

Pediatric Case Definition[edit | edit source]

  • 2006, A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome[7] (Full Text)

Clinical Trials[edit | edit source]

The Hunter-Hopkins Center is currently one of two clinical sites participating in the Hemispherx Biopharma 511/open label Ampligen trials to gain FDA approval. Ampligen is an IV medication given twice weekly in the Hunter-Hopkins infusion room. For more information in this program please see this link: Ampligen study at Hunter-Hopkins.[8]

Clinic location[edit | edit source]

Hunter-Hopkins Center
7421 Carmel Executive Park Dr.
Charlotte, North Carolina 28226
Telephone: (704) 543-9692

Notable Studies[edit | edit source]

Talks & interviews[edit | edit source]

Grand Rounds Video
Grand Rounds Presentation Slide Deck

HHS/CFSAC Testimony[edit | edit source]

Open Letter to The Lancet[edit | edit source]

Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the ME/CFS field, signed the second letter.

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  2. "Cause of illness remains unknown," By Karen Garloch Published: May 5, 2009
  7. Jason, Leonard A; Jordan, Karen; Miike, Teruhisa; Bell, David S; Lapp, Charles; Torres-Harding, Susan; Rowe, Kathy; Gurwitt, Alan; De Meirleir, Kenny; Van Hoof, Elke LS (2006), "A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome" (PDF), Journal of Chronic Fatigue Syndrome, 13 (2-3): 1-44, doi:10.1300/J092v13n02_01 
  9. Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029 
  10. Unger, ER; Lin, JS; Brimmer, DJ; Lapp, CW; Komaroff, AL; Nath, A; Laird, S; Iskander, J (2016), "CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education", Morbidity and Mortality Weekly Report, 65 (5051): 1434–1438, doi:10.15585/mmwr.mm655051a4 
  11. Irlbeck, D. M., Vernon, S. D., McCleary, K. K., Bateman, L., Klimas, N. G., Lapp, C. W., Peterson, D.L., Brown, J. R., Remlinger, K. S., Wilfret, D. A., and Gerondelis, P. (2014). No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank. BMC Research Notes, 7, 461.
  12. Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963 
  13. Jason, Leonard; Porter, Nicole; Shelleby, E; Till, L; Bell, David S; Lapp, Charles W; Rowe, Kathy; De Meirleir, Kenny (2009), "Severe versus Moderate criteria for the new pediatric case definition for ME/CFS", Child Psychiatry and Human Development, 40 (4): 609-20, doi:10.1007/s10578-009-0147-8 
  14. Van Hoof, E; De Becker, P; Lapp, C; Cluydts, R; De Meirleir, K (2007), "Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome", The American Journal of the Medical Sciences, 333 (2): 78-84, PMID 17301585 
  15. Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 13, Iss. 2-3, pp. 89-96.
  16. Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. Journal of Chronic Fatigue Syndrome, Vol. 5, Iss. 3-4, pp. 207-221.
  17. Vojdani, A; Choppa, PC; Lapp, CW (1998), "Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome", J Clin Lab Immunol, 50 (1): 1-16, PMID 10189612 
  18. Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 3, Iss. 2, pp 59-76.

The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history